中华胰腺病杂志
中華胰腺病雜誌
중화이선병잡지
CHINESE JOURNAL OF PANCREATOLOGY
2012年
3期
153-155
,共3页
丁兆军%孙衍伟%陈希平%安永恒
丁兆軍%孫衍偉%陳希平%安永恆
정조군%손연위%진희평%안영항
胰腺肿瘤%放射疗法%药物疗法%氧%吉西他滨
胰腺腫瘤%放射療法%藥物療法%氧%吉西他濱
이선종류%방사요법%약물요법%양%길서타빈
Pancreatic neoplasms%Radiotherapy%Drug therapy%Oxygen%Gemcitabine
目的 评价低剂量健择同步高-低氧放射治疗局部晚期胰腺癌的临床疗效及不良反应.方法 将56例局部晚期胰腺癌患者按信封法随机分为放化疗组和化疗组.放化疗组采用低剂量健择(600 mg/m2)同步高-低氧放射治疗,化疗组采用足量健择( 1000 mg/m2)化疗,观察两组的近期疗效、远处转移率、临床获益率、生存率及不良反应.结果 放化疗组完全缓解1例,部分缓解15例,总有效率66.7％ (16/24),化疗组部分缓解9例,总有效率36.0％(9/25),两组差异具有统计学意义(X2=4.6082,P=0.0318)；两组临床获益率分别为83.3％ (20/24)和60.0％( 15/25),差异无统计学意义(P=0.0707)；远处转移率分别为66.7％ (16/24)和72.0％(18/25),差异无统计学意义(P =0.6855)；两组12、24个月生存率分别为62.5％和32.0％、37.5％和12.0％,差异均具有统计学意义(P值分别为0.0325、0.0380)；严重不良反应发生率分别为45.8％和40.0％,差异无统计学意义(P =0.6800).结论 低剂量健择同步高-低氧放射治疗局部晚期胰腺癌在总有效率及12、24个月生存率方面优于足量健择化疗,不良反应无明显增加.
目的 評價低劑量健擇同步高-低氧放射治療跼部晚期胰腺癌的臨床療效及不良反應.方法 將56例跼部晚期胰腺癌患者按信封法隨機分為放化療組和化療組.放化療組採用低劑量健擇(600 mg/m2)同步高-低氧放射治療,化療組採用足量健擇( 1000 mg/m2)化療,觀察兩組的近期療效、遠處轉移率、臨床穫益率、生存率及不良反應.結果 放化療組完全緩解1例,部分緩解15例,總有效率66.7％ (16/24),化療組部分緩解9例,總有效率36.0％(9/25),兩組差異具有統計學意義(X2=4.6082,P=0.0318)；兩組臨床穫益率分彆為83.3％ (20/24)和60.0％( 15/25),差異無統計學意義(P=0.0707)；遠處轉移率分彆為66.7％ (16/24)和72.0％(18/25),差異無統計學意義(P =0.6855)；兩組12、24箇月生存率分彆為62.5％和32.0％、37.5％和12.0％,差異均具有統計學意義(P值分彆為0.0325、0.0380)；嚴重不良反應髮生率分彆為45.8％和40.0％,差異無統計學意義(P =0.6800).結論 低劑量健擇同步高-低氧放射治療跼部晚期胰腺癌在總有效率及12、24箇月生存率方麵優于足量健擇化療,不良反應無明顯增加.
목적 평개저제량건택동보고-저양방사치료국부만기이선암적림상료효급불량반응.방법 장56례국부만기이선암환자안신봉법수궤분위방화료조화화료조.방화료조채용저제량건택(600 mg/m2)동보고-저양방사치료,화료조채용족량건택( 1000 mg/m2)화료,관찰량조적근기료효、원처전이솔、림상획익솔、생존솔급불량반응.결과 방화료조완전완해1례,부분완해15례,총유효솔66.7％ (16/24),화료조부분완해9례,총유효솔36.0％(9/25),량조차이구유통계학의의(X2=4.6082,P=0.0318)；량조림상획익솔분별위83.3％ (20/24)화60.0％( 15/25),차이무통계학의의(P=0.0707)；원처전이솔분별위66.7％ (16/24)화72.0％(18/25),차이무통계학의의(P =0.6855)；량조12、24개월생존솔분별위62.5％화32.0％、37.5％화12.0％,차이균구유통계학의의(P치분별위0.0325、0.0380)；엄중불량반응발생솔분별위45.8％화40.0％,차이무통계학의의(P =0.6800).결론 저제량건택동보고-저양방사치료국부만기이선암재총유효솔급12、24개월생존솔방면우우족량건택화료,불량반응무명현증가.
Objective To evaluate the efficacy and adverse effects of low doses gemcitabine chemotherapy combined with synchronous high-low oxygen radiotherapy in patients with locally advanced pancreatic cancer.Methods Fifty-six patients with locally advanced pancreatic cancer were randomly divided into two groups by envelop method:radio-chemotherapy group or chemotherapy group.Patients in radio-chmotherapy group were treated with low doses of gemcitabine chemotherapy ( 600 mg/m2 ) combined with high-low oxygen radiotherapy synchronously,paients in chmotherapy group were treated with full doses of gemcitabine chemotherapy ( 1000 mg/m2).The short-term effect,distant metastasis rate,clinical benefit rate,survival rate and adverse events of two groups were observed.Results There was one patient achievedcomplete relief and 15 patients achieved partial relief in radio-chemotherapy group with an overall effective rate of 66.7％ (16/24) ; there were 9 patients achieved partial relief in chemotherapy group with an overall effective rate of 36.0％ (9/25),the difference between the two groups was statistically significant (X2 =4.6082,P =0.0318 ).The clinical benefit rates were 83.3 ％ ( 20/24 ) and 60％ ( 15/25 ),respectively,the difference between the two groups was not statistically significant ( P =0.070).The distant metastasis rates were 66.7％(16/24) and 72％ (18/25),respectively,the difference between the two groups was not statistically significant (P =0.6855).The 12,24 months survival rates were 62.5％ vs 32％,37.5％ vs 12％,the difference between the two groups was statistically significant ( P =0.0325,0.0380).The incidence of serious adverse events was 45.8％ and 4 0 ％ without statistical difference.Conclusions Low doses of gemcitabine chemotherapy combined with high-low oxygen radiotherapy synchronously is better than full doses of gemcitabine chemotherapy with regard to total effective rates and 12,24 months survival rates,with no obvious increase in the incidence of serious adverse events.
